Aclaris Therapeutics (NASDAQ:ACRS) Receives Buy Rating from HC Wainwright

Aclaris Therapeutics (NASDAQ:ACRS)‘s stock had its “buy” rating restated by equities research analysts at HC Wainwright in a research report issued on Wednesday,Benzinga reports. They presently have a $16.00 target price on the biotechnology company’s stock. HC Wainwright’s price objective would indicate a potential upside of 261.17% from the company’s current price.

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Aclaris Therapeutics in a research note on Monday, December 29th. Five equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $9.75.

Aclaris Therapeutics Trading Up 69.1%

Shares of ACRS stock opened at $4.43 on Wednesday. The company has a market capitalization of $479.97 million, a price-to-earnings ratio of -3.21 and a beta of 0.41. Aclaris Therapeutics has a twelve month low of $1.05 and a twelve month high of $4.89. The firm has a 50-day moving average price of $2.87 and a 200 day moving average price of $2.23.

Aclaris Therapeutics (NASDAQ:ACRS) last posted its quarterly earnings results on Thursday, November 6th. The biotechnology company reported ($0.12) EPS for the quarter, beating the consensus estimate of ($0.13) by $0.01. The company had revenue of $3.30 million during the quarter, compared to analysts’ expectations of $1.59 million. Aclaris Therapeutics had a negative return on equity of 39.73% and a negative net margin of 900.01%. As a group, research analysts predict that Aclaris Therapeutics will post -0.82 earnings per share for the current year.

Institutional Trading of Aclaris Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Raymond James Financial Inc. boosted its position in shares of Aclaris Therapeutics by 2.2% during the third quarter. Raymond James Financial Inc. now owns 283,476 shares of the biotechnology company’s stock valued at $539,000 after buying an additional 6,217 shares during the last quarter. Rhumbline Advisers increased its holdings in Aclaris Therapeutics by 7.4% during the third quarter. Rhumbline Advisers now owns 91,236 shares of the biotechnology company’s stock worth $173,000 after buying an additional 6,271 shares during the last quarter. BNP Paribas Financial Markets raised its position in Aclaris Therapeutics by 59.0% in the third quarter. BNP Paribas Financial Markets now owns 26,667 shares of the biotechnology company’s stock worth $51,000 after acquiring an additional 9,894 shares during the period. AXQ Capital LP purchased a new position in Aclaris Therapeutics in the third quarter valued at about $27,000. Finally, ProShare Advisors LLC purchased a new position in Aclaris Therapeutics in the second quarter valued at about $26,000. 98.34% of the stock is owned by institutional investors and hedge funds.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc (NASDAQ:ACRS) is a clinical‐stage biopharmaceutical company focused on discovering, developing and commercializing novel small‐molecule therapies for dermatologic diseases and related rare disorders. The company’s pipeline includes several product candidates designed to address chronic inflammatory skin conditions and non‐melanoma skin lesions. Lead programs include ATI‐50002, a topical agent in late‐stage development for molluscum contagiosum removal; ATI‐50003 for common wart resolution; ATI‐1501, an oral JAK1/2 inhibitor targeting pruritic disorders; and ATI‐450, an oral MK2 inhibitor for inflammatory indications.

Founded in 2016 and headquartered in Malvern, Pennsylvania, Aclaris leverages proprietary chemistry platforms and translational research capabilities to advance multiple clinical and preclinical candidates.